Navigation Links
ULURU Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

on identifying the right strategic partner. We are pleased to announce that we are in discussions with multiple wound care companies and we plan to conclude negotiations by the end of the year".

Operating Results

Revenue for the second quarter of 2009 was $136,000, compared to $96,000 for the second quarter of 2008. The increase of approximately $40,000 in revenue from the second quarter of 2008 compared to the second quarter of 2009 was due to an increase in Altrazeal(TM) product sales of $47,000 and $15,000 in sponsored research as the prior year included a non-recurring revenue adjustment. These revenue increases were partially offset by a decrease of $10,000 in Zindaclin(R) royalties.

Research and development expenses for the second quarter of 2009 were $854,000, including $213,000 in share-based compensation, compared to $888,000, including $40,000 in share-based compensation, for the second quarter of 2008. The decrease of approximately $33,000 in research and development expenses was primarily due to lower product development costs of $265,000 associated with our Altrazeal(TM) and OraDisc(TM) technologies. This decrease was partially offset by an increase of $96,000 in regulatory expenses for consultants engaged for our regulatory filings for Altrazeal(TM) related products, increased clinical testing expenses of $21,000 for Altrazeal(TM) and Altrazeal(TM) Silver, and additional compensation costs of approximately $125,000, primarily for the vesting of certain restricted stock awards associated with the Company's workforce reduction in June 2009.

Selling, general and administrative expenses for the second quarter of 2009 were $1.8 million, including $279,000 in share-based compensation, compared to $1.3 million, including $220,000 in share-based compensation, for the second quarter of 2008. The increase of approximately $0.5 million in selling, general and administrative expen
'/>"/>

SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
10. ULURU Inc. Reports First Quarter 2008 Financial Results
11. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Pepsi Bottling Group, ArvinMeritor, Inc., ... are among the major employers that implemented Thomson ... their employees make better decisions about their benefits. ... personalized summary of their families, use of healthcare ... this personalized information, employees can determine which of ...
(Date:12/14/2009)... Haemonetics Corporation (NYSE: HAE ) announced ... action to stop Fenwal Inc.,s continued patent infringement ... kits, using a modified separation chamber. Fenwal ... patent and the injunction entered by the Court ... December 1, 2010. According to statements made ...
(Date:12/14/2009)... To Wear Pink(TM) (TETWP), the grassroots cowboy campaign ... at the signature Tough Enough To Wear Pink ... NFR) in Las Vegas. While pink is not ... of the western industry and rodeo fans was ... hats, bracelets and more. ,, Through the ...
(Date:12/14/2009)... up 900-Member Physician Staff , ... La Jolla, Calif. ... elected Marc Sedwitz, MD, as the new chief of staff of ... the 900-member physician team on Jan. 1, 2010. , , , ... staff liaison to Scripps La Jolla’s administrative staff and its board ...
(Date:12/14/2009)... Tens of Thousands of New Chronic Hepatitis Infections ... Legislation approved by Congress providing for federal funding ... to reduce tens of thousands of new viral ... States, the National Viral Hepatitis Roundtable ... in the FY 2010 Consolidated Appropriations bill approved ...
Breaking Medicine News(10 mins):Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2
... IRVINE, Calif., Jan. 19 PatientFYI,( http://www.patientfyi.com ), ... way patients select doctors, debuted this week with ... dentists,including over 50,000 with enhanced Practice Profiles. , ... improved the way sellers present their,strengths, and buyers ...
... Awards)PHILADELPHIA, Jan. 19 GlaxoSmithKline, one of the ... announced the recipients of the GlaxoSmithKline 12th Annual ... services. Each Pennsylvania-based nonprofit will receive a $40,000 ... Tuesday, March 17 at GlaxoSmithKline in Philadelphia where ...
... WASHINGTON, Jan. 19 The U.S. bishops urged ... that protect conscience rights of health care workers, ... ban funding of stem cell research that encourages ... a January 16 letter from Cardinal Francis George, ...
... Center for Health Innovation Discusses the Impact of the Economic ... A new report released today ... advisory firm to health providers, has found that hospitals and ... both capital spending and unprofitable healthcare services as a result ...
... bank, experts say , , MONDAY, Jan. 19 (HealthDay News) ... but you don,t have to shortchange your health. , Experts ... live healthy and cut their risk of cancer without breaking ... , Get moving . Moderate to intensive aerobic exercise, ...
... Jan. 19 Back in 2000 Katie Couric told Americans ... -- but only if you get tested in time . ... that according to the National Cancer Institute (NCI), as recently ... certain whether colonoscopy can help reduce the number of deaths ...
Other Medicine News:Health News:PatientFYI is Revolutionizing the Way Patients Find the Best Doctors to Serve Their Needs 2Health News:PatientFYI is Revolutionizing the Way Patients Find the Best Doctors to Serve Their Needs 3Health News:GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding 2Health News:GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding 3Health News:GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding 4Health News:Bishops Urge New President to Keep Laws on Conscience Rights, Foreign Aid for Abortion, Embryonic Stem Cell Research 2Health News:Bishops Urge New President to Keep Laws on Conscience Rights, Foreign Aid for Abortion, Embryonic Stem Cell Research 3Health News:Bishops Urge New President to Keep Laws on Conscience Rights, Foreign Aid for Abortion, Embryonic Stem Cell Research 4Health News:Bishops Urge New President to Keep Laws on Conscience Rights, Foreign Aid for Abortion, Embryonic Stem Cell Research 5Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 2Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 3Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 4Health News:Low-Cost Strategies to Maintain Health in Hard Times 2Health News:Katie Couric Misrepresented Screening Benefits - Claims 'Death By Colonoscopy' Expose 2
(Date:12/14/2009)... Caliper Life ... provider of tools and services for drug discovery ... has completed the sale of Xenogen Biosciences Corporation ... services, to Taconic Farms, Inc. for approximately $11 ... part of Caliper,s acquisition of Xenogen Corporation in ...
(Date:12/14/2009)... The U.S. Food and Drug Administration (FDA) ... Suspension for the treatment of schizophrenia in adults, ... ) announced today. ZYPREXA RELPREVV, a long-acting intramuscular ... to four weeks. ,, Different from both oral ... allow for stable concentrations of the active drug ...
(Date:12/14/2009)... Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) ... directors with the addition of Lt. Gen. Ronald R. ... of Martin, Blanck & Associates, a federal health services ... addition, the company board now has nine members. ,, ... a medical officer and battalion surgeon in Vietnam. He ...
Breaking Medicine Technology:Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 2Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 3Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 2FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 5FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 6FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 7FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 8Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Health Experts Praise Intellicig Electronic Cigarette 54824 1Health Experts Praise Intellicig Electronic Cigarette 54824 2Health Experts Praise Intellicig Electronic Cigarette 54824 3Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 1Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 2Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 3Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 4Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 5Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 6Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 7Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 8Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 9Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 10Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 11Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 12Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 13Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 14Iterative reconstruction technique significantly reduces patient radiation dose during CT scans 54816 1
... U.S., U.K. and China TrialsSAN DIEGO, Jan. 7 ... liver disease, today announced patient enrollment has begun for ... will study the Extracorporeal Liver Assist Device (ELAD) as ... under three protocols. The study is open for enrollment ...
... NEW YORK, Jan. 6 The Michael J. Fox ... four industry research teams for pre-clinical research on potential ... the Foundation,s Therapeutics Development Initiative. This program, ... on Parkinson,s research. TDI is part of ...
Other Medicine Technology:ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2
The Icy catheter is inserted into the femoral vein and resides in the inferior vena cava. Saline flow within the balloons creates a proprietary vortex flow pattern which maximizes heat exchange with...
...
Our smallest port is available with or without a COOK Peel-Away Introducer Set....
The mid-sized polysulfone is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 0.9 mm....
Medicine Products: